Looking over Anika Therapeutics (ANIK) reminded me of one of my favorite Peter Lynch quotes: "When even the analysts are bored, it's time to start buying." According to the company's investor relations site, Anika is covered by three. During the Q1 2013 earnings call, only five analysts bothered tuning in. Let's see if this company is as boring as it seems.
Anika makes therapeutic products involved in tissue protection, healing and repair. Anika's products are based on a naturally occurring, biocompatible polymer, called hyaluronan, or hyaluronic acid (HA). The company uses its proprietary technologies to modify the HA molecule and tailor it for specific, therapeutic applications.
Fundamentally sound and growing
According to the company's latest 10-Q filing,...
Only subscribers can access this article, which is part of the PRO research library covering 3,609 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: